Yan Lin, de Leur Kitty, Hendriks Rudi W, van der Laan Luc J W, Shi Yunying, Wang Lanlan, Baan Carla C
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Front Immunol. 2017 Nov 7;8:1510. doi: 10.3389/fimmu.2017.01510. eCollection 2017.
Over the past decade, antibody-mediated (humoral) rejection has been recognized as a common cause of graft dysfunction after organ transplantation and an important determinant for graft loss. In humoral alloimmunity, T follicular helper (Tfh) cells play a crucial role, because they help naïve B cells to differentiate into memory B cells and alloantibody-producing plasma cells within germinal centers. In this way, they contribute to the induction of donor-specific antibodies, which are responsible for the humoral immune response to the allograft. In this article, we provide an overview of the current knowledge on the effects of immunosuppressive therapies on Tfh cell development and function, and discuss possible new approaches to influence the activity of Tfh cells. In addition, we discuss the potential use of Tfh cells as a pharmacodynamic biomarker to improve alloimmune-risk stratification and tailoring of immunosuppression to individualize therapy after transplantation.
在过去十年中，抗体介导的（体液性）排斥反应已被公认为器官移植后移植物功能障碍的常见原因以及移植物丢失的重要决定因素。在体液性同种免疫中，滤泡辅助性T（Tfh）细胞发挥着关键作用，因为它们帮助幼稚B细胞在生发中心分化为记忆B细胞和产生同种抗体的浆细胞。通过这种方式，它们有助于诱导供体特异性抗体，而这些抗体负责对同种异体移植物的体液免疫反应。在本文中，我们概述了目前关于免疫抑制疗法对Tfh细胞发育和功能影响的知识，并讨论了影响Tfh细胞活性的可能新方法。此外，我们还讨论了将Tfh细胞用作药效学生物标志物以改善同种免疫风险分层以及调整免疫抑制以实现移植后个体化治疗的潜在用途。
